Exact Mass: 473.3293618
Exact Mass Matches: 473.3293618
Found 81 metabolites which its exact mass value is equals to given mass value 473.3293618
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(9S,10E,12S,13S)-9,12,13-Trihydroxyoctadec-10-enoylcarnitine
(9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an (9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9S,10E,12S,13S)-9,12,13-trihydroxyoctadec-10-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9S,10R,11E,13S)-9,10,13-Trihydroxyoctadec-11-enoylcarnitine
(9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoylcarnitine is an acylcarnitine. More specifically, it is an (9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9S,10R,11E,13S)-9,10,13-trihydroxyoctadec-11-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Ala Lys Lys Lys
C21H43N7O5 (473.33255080000004)
Ile Ile Lys Thr
C22H43N5O6 (473.32131780000003)
Ile Ile Thr Lys
C22H43N5O6 (473.32131780000003)
Ile Lys Ile Thr
C22H43N5O6 (473.32131780000003)
Ile Lys Leu Thr
C22H43N5O6 (473.32131780000003)
Ile Lys Thr Ile
C22H43N5O6 (473.32131780000003)
Ile Lys Thr Leu
C22H43N5O6 (473.32131780000003)
Ile Leu Lys Thr
C22H43N5O6 (473.32131780000003)
Ile Leu Thr Lys
C22H43N5O6 (473.32131780000003)
Ile Thr Ile Lys
C22H43N5O6 (473.32131780000003)
Ile Thr Lys Ile
C22H43N5O6 (473.32131780000003)
Ile Thr Lys Leu
C22H43N5O6 (473.32131780000003)
Ile Thr Leu Lys
C22H43N5O6 (473.32131780000003)
Lys Ala Lys Lys
C21H43N7O5 (473.33255080000004)
Lys Ile Ile Thr
C22H43N5O6 (473.32131780000003)
Lys Ile Leu Thr
C22H43N5O6 (473.32131780000003)
Lys Ile Thr Ile
C22H43N5O6 (473.32131780000003)
Lys Ile Thr Leu
C22H43N5O6 (473.32131780000003)
Lys Lys Ala Lys
C21H43N7O5 (473.33255080000004)
Lys Lys Lys Ala
C21H43N7O5 (473.33255080000004)
Lys Leu Ile Thr
C22H43N5O6 (473.32131780000003)
Lys Leu Leu Thr
C22H43N5O6 (473.32131780000003)
Lys Leu Thr Ile
C22H43N5O6 (473.32131780000003)
Lys Leu Thr Leu
C22H43N5O6 (473.32131780000003)
Lys Thr Ile Ile
C22H43N5O6 (473.32131780000003)
Lys Thr Ile Leu
C22H43N5O6 (473.32131780000003)
Lys Thr Leu Ile
C22H43N5O6 (473.32131780000003)
Lys Thr Leu Leu
C22H43N5O6 (473.32131780000003)
Leu Ile Lys Thr
C22H43N5O6 (473.32131780000003)
Leu Ile Thr Lys
C22H43N5O6 (473.32131780000003)
Leu Lys Ile Thr
C22H43N5O6 (473.32131780000003)
Leu Lys Leu Thr
C22H43N5O6 (473.32131780000003)
Leu Lys Thr Ile
C22H43N5O6 (473.32131780000003)
Leu Lys Thr Leu
C22H43N5O6 (473.32131780000003)
Leu Leu Lys Thr
C22H43N5O6 (473.32131780000003)
Leu Leu Thr Lys
C22H43N5O6 (473.32131780000003)
Leu Thr Ile Lys
C22H43N5O6 (473.32131780000003)
Leu Thr Lys Ile
C22H43N5O6 (473.32131780000003)
Leu Thr Lys Leu
C22H43N5O6 (473.32131780000003)
Leu Thr Leu Lys
C22H43N5O6 (473.32131780000003)
Thr Ile Ile Lys
C22H43N5O6 (473.32131780000003)
Thr Ile Lys Ile
C22H43N5O6 (473.32131780000003)
Thr Ile Lys Leu
C22H43N5O6 (473.32131780000003)
Thr Ile Leu Lys
C22H43N5O6 (473.32131780000003)
Thr Lys Ile Ile
C22H43N5O6 (473.32131780000003)
Thr Lys Ile Leu
C22H43N5O6 (473.32131780000003)
Thr Lys Leu Ile
C22H43N5O6 (473.32131780000003)
Thr Lys Leu Leu
C22H43N5O6 (473.32131780000003)
Thr Leu Ile Lys
C22H43N5O6 (473.32131780000003)
Thr Leu Lys Ile
C22H43N5O6 (473.32131780000003)
Thr Leu Lys Leu
C22H43N5O6 (473.32131780000003)
Thr Leu Leu Lys
C22H43N5O6 (473.32131780000003)
(9S,10E,12S,13S)-9,12,13-Trihydroxyoctadec-10-enoylcarnitine
(9S,10R,11E,13S)-9,10,13-Trihydroxyoctadec-11-enoylcarnitine
N-[(5R,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(4R,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4R,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7R,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(5R,6R,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4R,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(4S,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H43N3O4 (473.32533980000005)
N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5R,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5R,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)
N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C27H43N3O4 (473.32533980000005)